MedTrace Logo

COgnitioN With VERiciGuat Evaluation in Heart Failure

NCT06601465 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-07-31

No results posted yet for this study

Summary

CONVERGE-HF is a 4-center pilot phase IIb randomized control trial in ambulatory patients with chronic heart failure (≥ 6 months) and mild-to-moderate cognitive impairment.

Conditions

Interventions

DRUG

Vericiguat

Tablet - 2.5 mg, 5 mg, 10 mg

Sponsors & Collaborators

  • Ottawa Heart Institute Research Corporation

    collaborator OTHER

  • Heart and Stroke Foundation of Canada

    collaborator OTHER

  • University of Alberta

    lead OTHER

Principal Investigators

  • Justin Ezekowitz, MBBCh, MSc · University of Alberta

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-03
Primary Completion
2026-07-31
Completion
2027-05-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06601465 on ClinicalTrials.gov